Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0017536 (giardiasis)
 1,714 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We reported a clinical case of a child with Giardiasis whose clinical symptoms show some common aspects (acute diarrhea, abdominal pain) with others less known (irido-keratoconjunctivitis) or even rare (acute interstitial nephritis).
 ...
PMID:[Giardiasis: a clinical case with rare symptomatology]. 324 60

10,000 faeces samples-from 9,120 adults and 880 children were examined to evaluate the faecal excretions. Giardia intestinalis was identified in 111 of those samples (84 adults and 27 children). A higher infection rate of G. Intestinalis was observed in child and male adult groups. Nitrogen excretion was evaluated and compared with fat excretion for the first time in the case of giardiasis. When malabsorption was obvious, both fat and nitrogen increased with generally moderate values. The malabsorption was much more frequent among children (88.9%) than among adults (26%) (p less than 0.001). These results could explain the fast settlement and the frequency of growth troubles in childhood. Giardiasis should be systematically and carefully investigated in a malabsorption in the person of a child.
 ...
PMID:[Giardia intestinalis: comparative study of lipid and nitrogen fecal excretions in adults and children with parasites]. 353 27

Fourteen calves, 12 days to 12 weeks old, were treated for diarrhea. Fecal examination for parasitologic, bacteriologic, or viral infection revealed Giardia in all calves; rotavirus and coronavirus were found in some calves. Thirteen affected calves were treated orally with dimetridazole (50 mg/kg of body weight, daily, for 5 days), with complete resolution of the diarrhea and elimination of the Giardia. Giardiasis should be considered as an etiologic agent of diarrhea in calves.
 ...
PMID:Diagnosis of Giardia infection in 14 calves. 367 73

A suspension of benzoylmetronidazole (6.4% w/v) was given orally at a dose of 15-25 ml, equivalent to 0.6-1 g metronidazole, once a day for three days to 11 children with giardiasis. Blood samples were collected after the first and third doses for analysis of plasma metronidazole and its main oxidative metabolite by high performance liquid chromatography. Peak metronidazole concentrations were 22.60 +/- 8.52 mg/l (mean +/- S.D.) after the first dose, and 30.22 +/- 10.06 mg/l after the third dose, occurring at 3.6 +/- 1.4 and 4.4 +/- 2.9 hours post-dose, respectively. Peak concentrations of the metabolite were 4.26 +/- 1.94 mg/l after the first dose and 7.96 +/- 3.63 mg/l after the third dose, occurring 7.2 +/- 1.6 and 9.1 +/- 3.3 h post-dose, respectively. Calculation of plasma metronidazole half-life and clearance values was not possible. This study shows that oral administration of metronidazole as its benzoyl ester slows the rate of metronidazole absorption, followed by sustained plasma concentrations and a prolonged elimination phase. Giardiasis does not appear to prevent metronidazole absorption. Concurrent giardiasis is unlikely to influence metronidazole therapy for systemic anaerobic infections.
 ...
PMID:Metronidazole metabolism following oral benzoylmetronidazole suspension in children with giardiasis. 375 32

Giardiasis is the number one parasite-caused gastrointestinal illness in the United States. It can be acquired through various water sources or the fecal-oral route. The detection and treatment of giardiasis can be difficult. Nurse practitioners, as primary health care providers, often see patients presenting with gastrointestinal complaints. These complaints could represent one of many illnesses, including giardiasis. Presented is a review of the background and current information available on Giardia necessary for appropriate evaluation and care of patients with suspected giardiasis.
 ...
PMID:Giardiasis: diagnosis and treatment. 378 81

In 25 patients with diagnostic of Giardiasis by duodenal intubation we studied the hepatic functional tests and hepatic biopsy. 60% of patients presented alterations of hepatic histology; 36% steatosis and 24% inflammatory lesions, chronic persistent hepatitis 3 cases and chronic active hepatitis two of them. Hepatic lesions regression was reached only with antiparasitic treatment and in some cases reappearance of lesions depended on parasitic's reinfections. For every patient with histologic diagnosis of chronic hepatitis without viral markers we suggested to dismiss Giardiasis and to treat it before to undergo other therapeutical behavior.
 ...
PMID:[Hepatic manifestations in giardiasis]. 383 66

Generalized edema and ascites were the main presenting features of giardiasis in a 3-year-old boy. Hypoalbuminemia, jejunal villous atrophy, Giardia lamblia in the duodenal aspirate, and abnormal gastrointestinal protein loss were present before therapy with metronidazole. Eradication of parasites resulted in complete clinical, histological, and biochemical remission. Giardiasis must now be included in the etiology of protein-losing enteropathy.
 ...
PMID:Giardiasis with protein-losing enteropathy. 398 70

A high index of suspicion and careful application of diagnostic methods are essential for accurate diagnosis of parasitic bowel diseases. The varied clinical spectrum of giardiasis, amebiasis, and strongyloidiasis emphasizes the need to consider these pathogens when patients present with gastrointestinal complaints. Giardiasis should be suspected in patients, especially returned travelers, with unexplained increase in stool frequency, particularly with bloating, flatulence, or vague systemic symptoms. Amebiasis must be considered in the differential diagnosis of any patient who presents with persistent diarrhea or signs of inflammatory bowel disease. Unexplained diarrheal illnesses associated with upper abdominal symptoms and eosinophilia should raise suspicion of the presence of strongyloidiasis. These findings in a patient with a compromised immune system or in a candidate for immunosuppressive therapy should prompt a thorough investigation to rule out this parasite, since disseminated strongyloidiasis often is fatal.
 ...
PMID:Parasitic bowel disease: three pathogens important in primary care. 628 Jan 60

Antibody response in giardiasis was measured by indirect fluorescent antibody (IFA) and enzyme-linked immunosorbent assays (ELISA) on serum samples of 125 patients. Twenty-nine of these patients had symptomatic giardiasis; 30 were asymptomatic (carriers); 40 had other parasitic infections; 16 had inflammatory bowel diseases; ten were normal subjects. It was found that those patients with symptomatic giardiasis had higher IFA titers compared with all patients who did not have giardiasis and patients who had asymptomatic giardiasis. Serum samples with titers of 1:64 or greater in Giardia IFA were absorbed with Giardia and other parasite antigens. Only absorption with Giardia caused the titers to fall significantly. The ELISA technique was less specific than the IFA technique. Giardiasis elicits a specific host antibody response that may be used as an adjunct in its diagnosis.
 ...
PMID:Diagnosis of giardiasis by two methods. Immunofluorescence and enzyme-linked immunosorbent assay. 635 1

Giardiasis is the most common pathogenic parasitic infection in the United States. The choice of a therapeutic agent for treatment of the infection is unclear; of the three drugs commonly used, metronidazole and furazolidone have been shown to be carcinogenic in animal studies, while quinarcrine causes frequent side effects. In order to evaluate the usefulness of these three drugs, eight randomized trials of effectiveness were evaluated. The trials suffered from unclear methods, variability in study populations and total dosage of medication used, inaccuracy in determining outcomes, and inadequate sample sizes. Both metronidazole and quinacrine were more effective than furazolidone (p less than 0.001), but quinacrine caused frequent side effects which may have been responsible for poor compliance. With regard to the carcinogenicity of these compounds, it appears likely that there is no large short-term risk from the use of metronidazole, but long-term follow-up studies have not been done and no clinical studies have been done regarding the risk of furazolidone or quinacrine. The lack of clear confidence in animal studies is evident in the fact that the Food and Drug Administration has approved ongoing studies with drugs related to metronidazole.
 ...
PMID:Issues in clinical parasitology: the treatment of giardiasis. 636 62


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>